China's Hemophilia B Gene Therapy: A Single Injection That Ends a Lifetime of Bleeding

Imagine a life where every cut, every bruise, every bump carries the risk of uncontrollable bleeding. Where a routine dental procedure requires weeks of preparation and thousands of dollars in clotting factor. Where spontaneous internal bleeding into joints destroys cartilage and leaves you wheelchair-bound by middle age.

Doctor consulting with patient about bleeding disorder treatment

This is the reality for people with hemophilia B, a rare genetic bleeding disorder affecting approximately 1 in 30,000 male births worldwide. Caused by mutations in the F9 gene, hemophilia B results in deficient or defective factor IX—a protein essential for blood clotting. Without functional factor IX, patients experience:

Spontaneous joint bleeds causing chronic pain and disability
Life-threatening internal bleeding requiring emergency intervention
Prolonged bleeding from minor injuries turning everyday activities into risks
Lifelong dependence on intravenous factor IX infusions 2-3 times per week

For decades, the only treatment was prophylactic factor IX replacement—injecting clotting factor every few days for life. While effective, this regimen costs approximately $300,000-$500,000 USD annually in Western countries, requires patients to become experts in self-injection, and still leaves them vulnerable to breakthrough bleeds.

But in April 2025, everything changed. China approved the first gene therapy for hemophilia B in Asia—a single intravenous infusion that promises to transform patients’ lives forever.

The Gene Therapy Revolution

Gene therapy represents one of medicine’s most audacious ideas: instead of treating symptoms, why not fix the underlying genetic defect? The concept is elegantly simple—deliver a functional copy of the missing gene directly to the patient’s cells, enabling them to produce the therapeutic protein themselves.

Asian doctor with syringe for treatment

For hemophilia B, this approach is particularly well-suited:

Single gene defect: Hemophilia B is caused by mutations in just one gene (F9), making it an ideal target for gene replacement
Well-understood biology: Scientists have studied factor IX for decades, knowing exactly how much is needed for therapeutic effect
Measurable outcomes: Blood clotting factor levels can be precisely measured, providing clear evidence of treatment success
Large therapeutic window: Even modest increases in factor IX levels dramatically reduce bleeding risk

The journey to approved gene therapy began in the 1990s with early clinical trials, but progress was slow. The first major breakthrough came in 2011, when researchers demonstrated that adeno-associated virus (AAV) vectors could safely deliver factor IX genes to liver cells.

In 2022, the first hemophilia B gene therapy (Hemgenix) was approved in the United States. Priced at $3.5 million USD per dose, it became the world’s most expensive drug. While clinically effective, the astronomical cost sparked debates about healthcare equity and access.

China’s answer came in 2025: yes, and at 1/9 the price.

China’s Historic Approval

On April 10, 2025, China’s National Medical Products Administration (NMPA) approved BBM-H901 (generic name: Dalnacogene Ponparvovec, brand name: Xinjiuning/信玖凝), making it the first gene therapy for hemophilia B approved in China and the first gene therapy for any rare disease approved in Asia.

Medical research laboratory for gene therapy development

The approval marked the culmination of nearly six years of development by Belief BioMed (信念医药), a Shanghai-based biotech company founded in 2018 by gene therapy pioneer Dr. Xiao Xiao. The company developed BBM-H901 using a proprietary engineered AAV capsid (AAV843) designed for optimal liver targeting.

Following approval, Takeda China (武田中国), the Chinese subsidiary of Japanese pharmaceutical giant Takeda Pharmaceutical Company, secured exclusive commercialization rights for BBM-H901 in mainland China, Hong Kong, and Macau.

Pricing: A New Paradigm for Gene Therapy Access

Perhaps the most striking aspect of BBM-H901’s launch is its price. At approximately ¥2.79 million RMB (about $380,000 USD), it costs roughly 1/9 the price of Hemgenix in the United States ($3.5 million USD). This dramatic cost difference—while still substantial—makes gene therapy accessible to far more patients than previously possible.

The pricing reflects several factors:

Domestic development: Research, clinical trials, and manufacturing conducted in China reduce costs
Government support: China’s National Major New Drug Innovation Program provided funding support
Local manufacturing: Production at Belief BioMed’s GMP facility in Shanghai eliminates import costs
Volume strategy: Lower margins with larger patient access versus maximum extraction from wealthy patients

China’s National Healthcare Security Administration has indicated that BBM-H901 is under evaluation for inclusion in the national drug reimbursement list, which would further reduce out-of-pocket costs for patients.

Clinical Results: From 58 to 2.9 Infusions Per Year

The clinical trial results that secured BBM-H901’s approval were published in Nature Medicine (November 2025), one of the world’s most prestigious medical journals.

Modern hospital for gene therapy treatment

Phase 3 Trial Design

The pivotal Phase 3 trial enrolled 26 adult male patients with moderately severe to severe hemophilia B (baseline factor IX levels <2% of normal) across multiple Chinese medical centers. Led by Professor Lei Zhang (张磊) and Professor Renchi Yang (杨仁池) at the Chinese Academy of Medical Sciences Blood Disease Hospital in Tianjin.

Remarkable Results

Outcome Measure	Baseline	Post-Treatment (Week 52)	Improvement
Mean Factor IX Activity	<1 IU/dL	55.1 IU/dL	5,400%+ increase
Annualized Bleeding Rate	6.0 events/year	0.6 events/year	90% reduction
Factor IX Infusions Required	58.2/year	2.9/year	95% reduction
Patients with Zero Bleeds	0%	80.8%	Dramatic improvement

Even more impressive were results from the investigator-initiated trial (IIT) that began in 2019. With over 5 years of follow-up for the earliest treated patients, BBM-H901 demonstrated:

Sustained factor IX expression: Stable therapeutic levels maintained years after single infusion
Durability: No significant decline in factor IX activity over time
Long-term safety: No late-onset adverse events or immune complications
Quality of life transformation: Patients reported freedom from the psychological burden of constant bleeding risk

One particularly striking case involved the world’s first hemophilia B patient to undergo total knee replacement without factor IX supplementation after gene therapy. Published in the New England Journal of Medicine (October 2022), this case demonstrated that BBM-H901 could restore factor IX levels sufficiently to support major surgery.

How AAV Gene Therapy Works

BBM-H901 represents a sophisticated application of adeno-associated virus (AAV) gene therapy technology.

Operating room for gene therapy procedures

The AAV Vector: Nature’s Delivery System

Adeno-associated viruses are small, non-pathogenic viruses that naturally infect humans without causing disease. Unlike other viral vectors used in gene therapy:

Non-integrating: AAV DNA remains in the cell nucleus as episomes, not inserting into chromosomes—eliminating cancer risk
Low immunogenicity: AAV typically provokes mild immune responses, making it suitable for systemic administration
Long-lasting expression: AAV-transduced cells can express therapeutic genes for years
Liver tropism: Certain AAV serotypes naturally target liver cells—exactly where factor IX is produced

The BBM-H901 Payload

Factor IX-Padua variant: A naturally occurring hyperactive variant with 8x higher specific activity than normal factor IX
Optimized codon usage: The gene sequence has been optimized for efficient protein production in human liver cells
Liver-specific promoter: Expression is driven by a promoter that maximizes production in hepatocytes

Chinese Medical Leadership

Asian doctors portrait for medical leadership

BBM-H901’s approval represents more than a scientific achievement—it signals China’s emergence as a global leader in gene therapy innovation.

Academic Excellence: The CAMS Blood Disease Hospital

The Chinese Academy of Medical Sciences Blood Disease Hospital (中国医学科学院血液病医院) in Tianjin, China’s only national-level specialized blood disease hospital, played a pivotal role in BBM-H901’s development. The hospital’s hematology department treats over 300,000 outpatients annually and has been designated as China’s National Clinical Research Center for Hematological Diseases.

Biotech Innovation: Belief BioMed

Founded in 2018 by Dr. Xiao Xiao, a pioneer in AAV vector biology who spent decades in U.S. academia before returning to China, Belief BioMed represents a new generation of Chinese biotech companies focused on innovative gene therapies. The company’s proprietary platform includes:

AAV vector engineering capabilities: Proprietary capsid variants optimized for specific tissue targeting
Large-scale manufacturing: GMP-compliant production facility in Shanghai
Robust pipeline: Multiple gene therapy candidates targeting hemophilia A, lysosomal storage diseases, and other genetic disorders

Medical Tourism: Access for International Patients

For international patients with hemophilia B, China’s approval of BBM-H901 creates unprecedented access to transformative gene therapy at a fraction of Western costs.

Leading Treatment Centers

Chinese Academy of Medical Sciences Blood Disease Hospital (Tianjin) — The lead clinical trial site with the most extensive experience
Peking Union Medical College Hospital (Beijing) — One of China’s top comprehensive hospitals
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Shanghai) — Major hemophilia treatment center in eastern China

Cost Comparison: Significant Savings

Cost Component	United States (Hemgenix)	China (BBM-H901)
Gene Therapy Drug	$3,500,000 USD	~$380,000 USD
Hospitalization	$15,000-25,000	$3,000-5,000
Pre/Post Monitoring	$10,000-15,000	$2,000-4,000
Total Estimated Cost	$3,525,000-3,540,000	$385,000-389,000

The cost savings are substantial—approximately $3.1 million USD less than U.S. treatment—even accounting for travel expenses.

The Future of Bleeding Disorder Treatment

BBM-H901’s approval represents just the beginning of gene therapy’s transformation of bleeding disorder treatment.

Next-Generation Gene Therapies

Hemophilia A gene therapy: More challenging than hemophilia B due to the larger factor VIII gene, but clinical trials are showing promise
Immune evasion technologies: New AAV capsids that evade pre-existing antibodies
Regulated expression: Gene therapies with built-in control mechanisms

Expanding Access

Macao approval (March 2026): BBM-H901 became the first hemophilia B gene therapy approved in Macao
Regional partnerships: Takeda is exploring pathways to make BBM-H901 available in other Asian markets
Insurance coverage expansion: Chinese provinces are evaluating gene therapy reimbursement policies

For the approximately 30,000 people worldwide living with hemophilia B, BBM-H901 represents the fulfillment of decades of hope. For millions more with other genetic diseases, it signals that the era of curative gene therapies has truly begun—with China positioned as a leading force in making these treatments accessible globally.

Sources

← Back to News